Alkem Laboratories share news, announcements and annual reports
NSE: ALKEMBSE: 539523Pharmaceuticals & BiotechnologyMid Cap
Alkem Laboratories Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2015
Last close ₹5,113.50up ₹34.50 (0.68%)BSE ₹5,125.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹5,079.00.
30 Oct: open ₹5,060.50, high ₹5,134.50, low ₹5,030.00
52-week range of traded prices to 30 Oct 2026
₹4,811.00Low, 22 Oct 2026₹5,933.50High, 13 Jan 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹61,140 Cr164th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 28.34
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.42
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.04%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 16.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.11
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,08,03658.4% delivered
Alkem Laboratories disputes and clarifications
46 filed, newest first.
Jul 2026
1 Jul · Legal
May 2026
Apr 2026
Jan 2026
22 Jan · Legal
13 Jan · Legal
1 Jan · Legal
Dec 2025
30 Dec · Legal
30 Dec · Legal
30 Dec · Legal
29 Dec · Legal
26 Dec · Legal
4 Dec · Legal
Nov 2025
18 Nov · Legal
3 Nov · Legal
Oct 2025
1 Oct · Legal
Sep 2025
24 Sep · Legal
22 Sep · Legal
Jul 2025
25 Jul · Legal
Jun 2025
26 Jun · Legal
Exchange has sought clarification from Alkem Laboratories Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.13 Jun · Legal
6 Jun · Legal
Mar 2025
28 Mar · Legal
1 Mar · Legal
1 Mar · Legal
Feb 2025
28 Feb · Legal
28 Feb · Legal
28 Feb · Legal
27 Feb · Legal
18 Feb · Legal
14 Feb · Legal
4 Feb · Legal
3 Feb · Legal
Jan 2025
7 Jan · Legal
Dec 2024
28 Dec · Legal
28 Dec · Legal
25 Dec · Legal
11 Dec · Legal
Nov 2024
8 Nov · Legal
Dec 2021
22 Dec · Legal
Exchange has sought clarification from Alkem Laboratories Limited with respect to announcement dated 20-Dec-2021, regarding change in director(s) of the Company. On basis of above the Company is required to provide confirmation in compliance with SEBI Letter dated June 14, 2018 read alongwith NSE Circular dated June 20, 2018. The response of the Company is awaited.
Jun 2019
6 Jun · Legal
Exchange has sought clarification from Alkem Laboratories Limited with respect to announcement dated 30-May-2019, regarding Board meeting held on May 30, 2019. On basis of above the Company is required to clarify following: 1. Disclosure of relationships between directors (in case of appointment of a director) 2. Brief profile (in case of appointment). The response of the Company is awaited.
May 2017
29 May · Legal
Exchange has sought clarification from Alkem Laboratories Limited with respect to announcement dated 26-May-2017, regarding Appointment of Mr Dheeraj Sharma as Independent Director of the company w.e.f. May 26, 2017. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.
Jun 2016